Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 1
2019 1
2020 2
2021 1
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes.
Rinaldetti S, Zhou Q, Abbott JM, de Jong FC, Esquer H, Costello JC, Theodorescu D, LaBarbera DV. Rinaldetti S, et al. Among authors: esquer h. Int J Mol Sci. 2022 Sep 14;23(18):10605. doi: 10.3390/ijms231810605. Int J Mol Sci. 2022. PMID: 36142576 Free PMC article.
HTS discovery of PARP1-HPF1 complex inhibitors in cancer.
Kellett T, Noor R, Zhou Q, Esquer H, Sala R, Stojanovic P, Rudolph J, Luger K, LaBarbera DV. Kellett T, et al. Among authors: esquer h. SLAS Discov. 2023 Dec;28(8):394-401. doi: 10.1016/j.slasd.2023.10.003. Epub 2023 Oct 14. SLAS Discov. 2023. PMID: 37844763 Free PMC article.
Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.
Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Prigaro BJ, et al. Among authors: esquer h. J Med Chem. 2022 Mar 10;65(5):3943-3961. doi: 10.1021/acs.jmedchem.1c01778. Epub 2022 Feb 22. J Med Chem. 2022. PMID: 35192363 Free PMC article.
The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.
Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. Clune S, et al. Among authors: esquer h. Biomed Pharmacother. 2024 Jan;170:116037. doi: 10.1016/j.biopha.2023.116037. Epub 2023 Dec 20. Biomed Pharmacother. 2024. PMID: 38128184 Free PMC article.
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. Abbott JM, et al. Among authors: esquer h. Mol Cancer Ther. 2020 Aug;19(8):1598-1612. doi: 10.1158/1535-7163.MCT-20-0106. Epub 2020 Jun 4. Mol Cancer Ther. 2020. PMID: 32499299 Free PMC article.
Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Abraham AD, et al. Among authors: esquer h. J Med Chem. 2019 Nov 27;62(22):10182-10203. doi: 10.1021/acs.jmedchem.9b01065. Epub 2019 Nov 18. J Med Chem. 2019. PMID: 31675229 Free PMC article.
12 results